<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01178333</url>
  </required_header>
  <id_info>
    <org_study_id>678</org_study_id>
    <secondary_id>U01HL072268</secondary_id>
    <nct_id>NCT01178333</nct_id>
  </id_info>
  <brief_title>Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study</brief_title>
  <acronym>HIT-RADIO</acronym>
  <official_title>Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study (HIT-RADIO Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New England Research Institutes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New England Research Institutes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIT-RADIO is a study of patients who had a positive heparin PF-4 antibody test between
      1/21/2008 and 9/25/2008 at selected hospitals. The study will collect and analyse information
      that is already in the patients' medical records. Information about laboratory values (such
      as platelet counts), treatments (such as medications), and outcomes (such as blood clots,
      amputation, and death) will be included.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIT-RADIO is a retrospective chart-review study of patients who had a positive heparin PF-4
      antibody test between 1/21/2008 and 9/25/2008 at selected hospitals associated with the
      Transfusion Medicine/Hemostasis Clinical Trials Network .

      Heparin-induced thrombocytopenia (HIT) is a major complication of the administration of
      heparin and can result in life-threatening thrombosis with or without thrombocytopenia
      (HIT-T) or can produce thrombocytopenia without clinically symptomatic thrombosis (&quot;isolated&quot;
      HIT). Isolated heparin-induced thrombocytopenia is defined as a fall in platelet count
      associated with a positive heparin PF-4 antibody test, in the absence of clinically overt
      thrombosis. While the treatment of HIT-T (HIT with thrombosis) with anticoagulation is well
      established, the risks and treatment of isolated HIT are unclear.

      It is anticipated that this data analysis will provide a current overview of the implications
      of a positive heparin PF-4 antibody test in clinical practice. It should determine the
      percentage of positive heparin PF-4 antibody tests that are associated with thrombocytopenia
      and thrombosis (HIT-T) or &quot;isolated&quot; HIT at diagnosis and the subsequent major clinical
      outcomes of death, limb amputation/gangrene, and new thrombosis. No &quot;snapshot&quot; of such HIT
      patients has been conducted in the past decade and the results will be important in assessing
      the impact of HIT in current medical care as well as documenting current treatment
      strategies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Occurrence of a Composite Triple Endpoint Consisting of Death, Limb Amputation/Gangrene, and New Thrombosis</measure>
    <time_frame>From the time that the positive heparin PF-4 antibody test was drawn until hospital discharge or day 45, whichever occurred first.</time_frame>
    <description>The mean time to an event is estimated by the area under the survival function. If the largest time is an event time, then the survival function goes to zero at that time, and the mean survival estimate is finite. Otherwise, the mean time cannot be estimated and may lead to a bias.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Occurrence of a Composite Triple Endpoint Consisting of Death, Limb Amputation/Gangrene, and New Thrombosis</measure>
    <time_frame>From the time that the positive heparin PF-4 antibody test was drawn until hospital discharge or day 45, whichever occurred first.</time_frame>
    <description>The median survival time is reported by each group for the time to occurrence of a composite triple endpoint consisting of death, limb amputation/gangrene, and new thrombosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Death</measure>
    <time_frame>From the time the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
    <description>The mean time to an event is estimated by the area under the survival function. If the largest time is an event time, then the survival function goes to zero at that time, and the mean survival estimate is finite. Otherwise, the mean time cannot be estimated and may lead to a bias.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Death</measure>
    <time_frame>From the time the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
    <description>The median survival time is reported by each group for the time to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Occurrence of Limb Amputation or Limb Gangrene</measure>
    <time_frame>From the time the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
    <description>Due to the small number of events, the median or mean survival time could not be defined. Therefore, the number of subjects with limb amputation or limb gangrene was reported in &quot;Outcome Measure Data Table&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Occurrence of Radiographically Confirmed Thromboembolism</measure>
    <time_frame>From the time the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
    <description>The mean time to an event is estimated by the area under the survival function. If the largest time is an event time, then the survival function goes to zero at that time, and the mean survival estimate is finite. Otherwise, the mean time cannot be estimated and may lead to a bias. However, the median survival times could not be defined for all three groups, so the mean time was reported in &quot;Outcome Measure Data Table&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Occurrence of Major Bleeding</measure>
    <time_frame>From the time that the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
    <description>The mean time to an event is estimated by the area under the survival function. If the largest time is an event time, then the survival function goes to zero at that time, and the mean survival estimate is finite. Otherwise, the mean time cannot be estimated and may lead to a bias.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Occurrence of Major Bleeding</measure>
    <time_frame>From the time that the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
    <description>The median survival time is reported by each group for the time to occurrence of major bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With HIT With Thrombosis (HIT-T) and Isolated HIT</measure>
    <time_frame>From the date 5 days before the positive heparin PF-4 antibody test was drawn to the date it was drawn</time_frame>
    <description>Proportion of subjects who, at the time the positive heparin PF-4 antibody test was drawn, were in each of the following categories:
Group 1: Those with thrombosis and or without thrombocytopenia (HIT-T): 16% of 442 subjects.
Group 2: Those with thrombocytopenia but not thrombosis (Isolated HIT): 64% of 442 subjects.
Group 3: Those with neither thrombocytopenia nor thrombosis (Neither HIT-T nor Isolated HIT): 20% of 442 subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of Heparin Exposure - Unfractionated Heparin (UFH)</measure>
    <time_frame>Hospital admission to date the positive heparin PF-4 antibody test was drawn, or 28 days prior to the date it was drawn, whichever is later, through the date it was drawn</time_frame>
    <description>Two types of heparins are commonly used as anticoagulants - unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH). UFH has been used for the prevention and treatment of thrombosis for several decades.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type of Heparin Exposure - Low Molecular Weight Heparin (LMWH)</measure>
    <time_frame>Hospital admission to date the positive heparin PF-4 antibody test was drawn, or 28 days prior to the date it was drawn, whichever is later, through the date it was drawn</time_frame>
    <description>Two types of heparins are commonly used as anticoagulants - unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH). LMWHs are derived from UFH by depolymerization. Each LMWH product has a specific molecular weight distribution that determines its anticoagulant activity and duration of action.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship of the Heparin PF-4 (Platelet Factor 4) Antibody Titer to the Clinical Diagnosis</measure>
    <time_frame>From the time the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
    <description>Heparin PF-4 (platelet factor 4) optical density (OD) test results were the dichotomous outcome (&lt;1.0 vs. &gt;=1.0). Clinical diagnosis was three groups (HIT-T, Isolated HIT and No HIT). The Heparin PF-4 optical density test looks for antibodies to complexes of heparin combined with platelet factor 4. Higher optical density indicates higher antibody concentration. We could say that generally OD values above 0.4 are considered a positive result, and that the higher the OD, the greater the concentration of antibodies in the patient's blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship of the Heparin PF-4 Antibody Titer to the Degree of Thrombocytopenia</measure>
    <time_frame>From the time the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
    <description>Heparin PF-4 optical density (OD) test results were the dichotomous outcome (&lt;1.0 vs. &gt;=1.0). Nadir Platelet Count (x10^9 / L) was used for the degree of thrombocytopenia. The Heparin PF-4 optical density test looks for antibodies to complexes of heparin combined with platelet factor 4. Higher optical density indicates higher antibody concentration. We could say that generally OD values above 0.4 are considered a positive result, and that the higher the OD, the greater the concentration of antibodies in the patient's blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship of the Heparin PF-4 Antibody Titer to the Primary Endpoint</measure>
    <time_frame>From the time the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
    <description>Heparin PF-4 OD test results were the dichotomous outcome (&lt;1.0 vs. &gt;=1.0). Primary endpoint was the composite endpoint of death, limb amputation/gangrene, or new thrombosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Treatment (Non-heparin Anticoagulant) Used in Hospital</measure>
    <time_frame>From the time that the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
    <description>Types of treatment (direct thrombin inhibitor, fondaparinux, warfarin, no treatment) provided to subjects in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Treatment (Non-heparin Anticoagulant) Used at the Time of Discharge</measure>
    <time_frame>From the time that the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Platelet Recovery, Among Subjects With a Low Platelet Count When the Positive PF4 Antibody Test Was Drawn</measure>
    <time_frame>From the time that the nadir platelet count was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">668</enrollment>
  <condition>Heparin Induced Thrombocytopenia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with a positive heparin PF-4 antibody test drawn between 1/21/2008 and 9/25/2008
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects with a positive heparin PF-4 antibody test occurring between 1/21/2008
             and 9/25/2008

          -  Medical record available for the admission during which the positive heparin PF-4
             antibody test was obtained

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan F Assmann, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New England Research Institutes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Kuter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eliot Williams, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Friedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood Center of Wisconsin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Go, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gunderson Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keith McCrae, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ellis Neufeld, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynne Uhl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Judith Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Bussel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Ortel, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jodi Segal, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Konkle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bloodworks (Puget Sound Blood Center)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cindy Leissinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Raife, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ann Zimrin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland Greenebaum Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey McCullough, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nigel Key, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce Sachais, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Kiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Institute for Transfusion Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina, Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University School of Medicine</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunderson Clinic</name>
      <address>
        <city>LaCrosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2010</study_first_submitted>
  <study_first_submitted_qc>August 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2010</study_first_posted>
  <results_first_submitted>March 17, 2015</results_first_submitted>
  <results_first_submitted_qc>April 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 4, 2015</results_first_posted>
  <last_update_submitted>May 6, 2015</last_update_submitted>
  <last_update_submitted_qc>May 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombocytopenia</keyword>
  <keyword>Heparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of 668 consecutive patients with a positive heparin-PF4 ELISA test, 226 were excluded, primarily due to lack of recent heparin exposure. Of 442 eligible patients, 71 had HIT-T, 284 had Isolated HIT and 87 had no HIT.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>HIT-T</title>
          <description>Positive heparin-PF4 ELISA test and a thrombotic event associated with heparin exposure within the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), with or without thrombocytopenia.</description>
        </group>
        <group group_id="P2">
          <title>Isolated HIT</title>
          <description>Positive heparin-PF4 ELISA test and a nadir platelet count &lt;50% of baseline platelet count associated with heparin exposure in the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), without a thrombotic event.</description>
        </group>
        <group group_id="P3">
          <title>No HIT</title>
          <description>Positive heparin-PF4 ELISA test with heparin exposure in the preceding 5 days, but not meeting criteria for HIT-T or isolated HIT.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="284"/>
                <participants group_id="P3" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="284"/>
                <participants group_id="P3" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Of 668 consecutive patients with a positive heparin-PF4 ELISA test, 225 were excluded, primarily due to lack of recent heparin exposure. Of 442 eligible patients, 71 had HIT-T, 284 had Isolated HIT and 87 had no HIT.</population>
      <group_list>
        <group group_id="B1">
          <title>HIT-T</title>
          <description>Positive heparin-PF4 ELISA test and a thrombotic event associated with heparin exposure within the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), with or without thrombocytopenia.</description>
        </group>
        <group group_id="B2">
          <title>Isolated HIT</title>
          <description>Positive heparin-PF4 ELISA test and a nadir platelet count &lt;50% of baseline platelet count associated with heparin exposure in the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), without a thrombotic event.</description>
        </group>
        <group group_id="B3">
          <title>No HIT</title>
          <description>Positive heparin-PF4 ELISA test with heparin exposure in the preceding 5 days, but not meeting criteria for HIT-T or isolated HIT.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="284"/>
            <count group_id="B3" value="87"/>
            <count group_id="B4" value="442"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="16"/>
                    <measurement group_id="B2" value="59" spread="18"/>
                    <measurement group_id="B3" value="60" spread="19"/>
                    <measurement group_id="B4" value="60" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Platelet Count</title>
          <units>x 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="282" spread="268"/>
                    <measurement group_id="B2" value="270" spread="149"/>
                    <measurement group_id="B3" value="215" spread="172"/>
                    <measurement group_id="B4" value="261" spread="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heparin exposure this admission before Day 0: use (or non-use) of unfractionated heparin (UFH)</title>
          <description>Two types of heparins are commonly used as anticoagulants - unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH). Unfractionated heparin (UFH) has been used for the prevention and treatment of thrombosis for several decades.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Use of unfractionated heparin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="263"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-use of unfractionated heparin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heparin exposure this admission before Day 0: use (or non-use) of low molecular weight heparin</title>
          <description>Two types of heparins are commonly used as anticoagulants - unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH). Low molecular weight heparin (LMWH) is derived from UFH by depolymerization. Each LMWH product has a specific molecular weight distribution that determines its anticoagulant activity and duration of action.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Use of low molecular weight heparin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-use of low molecular weight heparin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heparin-PF4 (platelet factor 4) OD (optical density) test results</title>
          <description>The OD in the Heparin-PF4 OD test stands for optical density. The PF4 stands for platelet factor 4. The test looks for antibodies to complexes of heparin combined with platelet factor 4. Higher optical density indicates higher antibody concentration. We could say that generally OD values above 0.4 are considered a positive result, and that the higher the OD, the greater the concentration of antibodies in the patient’s blood.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than 1.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than or equal to 1.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Admitting service</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>CV/thoracic surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orthopedic surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medicine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Time to Death</title>
        <description>The mean time to an event is estimated by the area under the survival function. If the largest time is an event time, then the survival function goes to zero at that time, and the mean survival estimate is finite. Otherwise, the mean time cannot be estimated and may lead to a bias.</description>
        <time_frame>From the time the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIT-T</title>
            <description>Positive heparin-PF4 ELISA test and a thrombotic event associated with heparin exposure within the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), with or without thrombocytopenia.</description>
          </group>
          <group group_id="O2">
            <title>Isolated HIT</title>
            <description>Positive heparin-PF4 ELISA test and a nadir platelet count &lt;50% of baseline platelet count associated with heparin exposure in the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), without a thrombotic event.</description>
          </group>
          <group group_id="O3">
            <title>No HIT</title>
            <description>Positive heparin-PF4 ELISA test with heparin exposure in the preceding 5 days, but not meeting criteria for HIT-T or isolated HIT.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Death</title>
          <description>The mean time to an event is estimated by the area under the survival function. If the largest time is an event time, then the survival function goes to zero at that time, and the mean survival estimate is finite. Otherwise, the mean time cannot be estimated and may lead to a bias.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6" spread="1.43"/>
                    <measurement group_id="O2" value="35.4" spread="1.11"/>
                    <measurement group_id="O3" value="34.5" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>4.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>2.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Death</title>
        <description>The median survival time is reported by each group for the time to death.</description>
        <time_frame>From the time the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIT-T</title>
            <description>Positive heparin-PF4 ELISA test and a thrombotic event associated with heparin exposure within the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), with or without thrombocytopenia.</description>
          </group>
          <group group_id="O2">
            <title>Isolated HIT</title>
            <description>Positive heparin-PF4 ELISA test and a nadir platelet count &lt;50% of baseline platelet count associated with heparin exposure in the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), without a thrombotic event.</description>
          </group>
          <group group_id="O3">
            <title>No HIT</title>
            <description>Positive heparin-PF4 ELISA test with heparin exposure in the preceding 5 days, but not meeting criteria for HIT-T or isolated HIT.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Death</title>
          <description>The median survival time is reported by each group for the time to death.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" lower_limit="23.0">Due to lack of events, the upper interval of the median survival time could not be estimated.</measurement>
                    <measurement group_id="O2" value="NA">Due to lack of events, the median survival time and 95% confidence interval could not be estimated.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="29.0">Due to lack of events, the median survival time and the upper interval could not be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Occurrence of Limb Amputation or Limb Gangrene</title>
        <description>Due to the small number of events, the median or mean survival time could not be defined. Therefore, the number of subjects with limb amputation or limb gangrene was reported in &quot;Outcome Measure Data Table&quot;.</description>
        <time_frame>From the time the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIT-T</title>
            <description>Positive heparin-PF4 ELISA test and a thrombotic event associated with heparin exposure within the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), with or without thrombocytopenia.</description>
          </group>
          <group group_id="O2">
            <title>Isolated HIT</title>
            <description>Positive heparin-PF4 ELISA test and a nadir platelet count &lt;50% of baseline platelet count associated with heparin exposure in the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), without a thrombotic event.</description>
          </group>
          <group group_id="O3">
            <title>No HIT</title>
            <description>Positive heparin-PF4 ELISA test with heparin exposure in the preceding 5 days, but not meeting criteria for HIT-T or isolated HIT.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Occurrence of Limb Amputation or Limb Gangrene</title>
          <description>Due to the small number of events, the median or mean survival time could not be defined. Therefore, the number of subjects with limb amputation or limb gangrene was reported in &quot;Outcome Measure Data Table&quot;.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>4.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>40.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>11.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Occurrence of Radiographically Confirmed Thromboembolism</title>
        <description>The mean time to an event is estimated by the area under the survival function. If the largest time is an event time, then the survival function goes to zero at that time, and the mean survival estimate is finite. Otherwise, the mean time cannot be estimated and may lead to a bias. However, the median survival times could not be defined for all three groups, so the mean time was reported in &quot;Outcome Measure Data Table&quot;.</description>
        <time_frame>From the time the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIT-T</title>
            <description>Positive heparin-PF4 ELISA test and a thrombotic event associated with heparin exposure within the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), with or without thrombocytopenia.</description>
          </group>
          <group group_id="O2">
            <title>Isolated HIT</title>
            <description>Positive heparin-PF4 ELISA test and a nadir platelet count &lt;50% of baseline platelet count associated with heparin exposure in the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), without a thrombotic event.</description>
          </group>
          <group group_id="O3">
            <title>No HIT</title>
            <description>Positive heparin-PF4 ELISA test with heparin exposure in the preceding 5 days, but not meeting criteria for HIT-T or isolated HIT.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Occurrence of Radiographically Confirmed Thromboembolism</title>
          <description>The mean time to an event is estimated by the area under the survival function. If the largest time is an event time, then the survival function goes to zero at that time, and the mean survival estimate is finite. Otherwise, the mean time cannot be estimated and may lead to a bias. However, the median survival times could not be defined for all three groups, so the mean time was reported in &quot;Outcome Measure Data Table&quot;.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="0.48"/>
                    <measurement group_id="O2" value="26.1" spread="0.74"/>
                    <measurement group_id="O3" value="5.74" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>5.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>4.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Occurrence of Major Bleeding</title>
        <description>The mean time to an event is estimated by the area under the survival function. If the largest time is an event time, then the survival function goes to zero at that time, and the mean survival estimate is finite. Otherwise, the mean time cannot be estimated and may lead to a bias.</description>
        <time_frame>From the time that the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIT-T</title>
            <description>Positive heparin-PF4 ELISA test and a thrombotic event associated with heparin exposure within the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), with or without thrombocytopenia.</description>
          </group>
          <group group_id="O2">
            <title>Isolated HIT</title>
            <description>Positive heparin-PF4 ELISA test and a nadir platelet count &lt;50% of baseline platelet count associated with heparin exposure in the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), without a thrombotic event.</description>
          </group>
          <group group_id="O3">
            <title>No HIT</title>
            <description>Positive heparin-PF4 ELISA test with heparin exposure in the preceding 5 days, but not meeting criteria for HIT-T or isolated HIT.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Occurrence of Major Bleeding</title>
          <description>The mean time to an event is estimated by the area under the survival function. If the largest time is an event time, then the survival function goes to zero at that time, and the mean survival estimate is finite. Otherwise, the mean time cannot be estimated and may lead to a bias.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="1.54"/>
                    <measurement group_id="O2" value="26.5" spread="1.36"/>
                    <measurement group_id="O3" value="17.2" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.50</ci_lower_limit>
            <ci_upper_limit>5.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>3.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Occurrence of Major Bleeding</title>
        <description>The median survival time is reported by each group for the time to occurrence of major bleeding.</description>
        <time_frame>From the time that the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIT-T</title>
            <description>Positive heparin-PF4 ELISA test and a thrombotic event associated with heparin exposure within the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), with or without thrombocytopenia.</description>
          </group>
          <group group_id="O2">
            <title>Isolated HIT</title>
            <description>Positive heparin-PF4 ELISA test and a nadir platelet count &lt;50% of baseline platelet count associated with heparin exposure in the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), without a thrombotic event.</description>
          </group>
          <group group_id="O3">
            <title>No HIT</title>
            <description>Positive heparin-PF4 ELISA test with heparin exposure in the preceding 5 days, but not meeting criteria for HIT-T or isolated HIT.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Occurrence of Major Bleeding</title>
          <description>The median survival time is reported by each group for the time to occurrence of major bleeding.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" lower_limit="8.0" upper_limit="28.0"/>
                    <measurement group_id="O2" value="36.0" lower_limit="31.0">Due to lack of events, the upper interval of median survival time could not be estimated.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="16.0">Due to lack of events, the median survival time and the upper interval could not be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With HIT With Thrombosis (HIT-T) and Isolated HIT</title>
        <description>Proportion of subjects who, at the time the positive heparin PF-4 antibody test was drawn, were in each of the following categories:
Group 1: Those with thrombosis and or without thrombocytopenia (HIT-T): 16% of 442 subjects.
Group 2: Those with thrombocytopenia but not thrombosis (Isolated HIT): 64% of 442 subjects.
Group 3: Those with neither thrombocytopenia nor thrombosis (Neither HIT-T nor Isolated HIT): 20% of 442 subjects.</description>
        <time_frame>From the date 5 days before the positive heparin PF-4 antibody test was drawn to the date it was drawn</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIT-T</title>
            <description>Positive heparin-PF4 ELISA test and a thrombotic event associated with heparin exposure within the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), with or without thrombocytopenia.</description>
          </group>
          <group group_id="O2">
            <title>Isolated HIT</title>
            <description>Positive heparin-PF4 ELISA test and a nadir platelet count &lt;50% of baseline platelet count associated with heparin exposure in the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), without a thrombotic event.</description>
          </group>
          <group group_id="O3">
            <title>No HIT</title>
            <description>Positive heparin-PF4 ELISA test with heparin exposure in the preceding 5 days, but not meeting criteria for HIT-T or isolated HIT.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With HIT With Thrombosis (HIT-T) and Isolated HIT</title>
          <description>Proportion of subjects who, at the time the positive heparin PF-4 antibody test was drawn, were in each of the following categories:
Group 1: Those with thrombosis and or without thrombocytopenia (HIT-T): 16% of 442 subjects.
Group 2: Those with thrombocytopenia but not thrombosis (Isolated HIT): 64% of 442 subjects.
Group 3: Those with neither thrombocytopenia nor thrombosis (Neither HIT-T nor Isolated HIT): 20% of 442 subjects.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="284"/>
                    <measurement group_id="O3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Type of Heparin Exposure - Unfractionated Heparin (UFH)</title>
        <description>Two types of heparins are commonly used as anticoagulants - unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH). UFH has been used for the prevention and treatment of thrombosis for several decades.</description>
        <time_frame>Hospital admission to date the positive heparin PF-4 antibody test was drawn, or 28 days prior to the date it was drawn, whichever is later, through the date it was drawn</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIT-T</title>
            <description>Positive heparin-PF4 ELISA test and a thrombotic event associated with heparin exposure within the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), with or without thrombocytopenia.</description>
          </group>
          <group group_id="O2">
            <title>Isolated HIT</title>
            <description>Positive heparin-PF4 ELISA test and a nadir platelet count &lt;50% of baseline platelet count associated with heparin exposure in the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), without a thrombotic event.</description>
          </group>
          <group group_id="O3">
            <title>No HIT</title>
            <description>Positive heparin-PF4 ELISA test with heparin exposure in the preceding 5 days, but not meeting criteria for HIT-T or isolated HIT.</description>
          </group>
        </group_list>
        <measure>
          <title>Type of Heparin Exposure - Unfractionated Heparin (UFH)</title>
          <description>Two types of heparins are commonly used as anticoagulants - unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH). UFH has been used for the prevention and treatment of thrombosis for several decades.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of subjects with heparin exposure:UFH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="263"/>
                    <measurement group_id="O3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects without heparin exposure:UFH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <p_value_desc>P-value is to compare three groups.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Type of Heparin Exposure - Low Molecular Weight Heparin (LMWH)</title>
        <description>Two types of heparins are commonly used as anticoagulants - unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH). LMWHs are derived from UFH by depolymerization. Each LMWH product has a specific molecular weight distribution that determines its anticoagulant activity and duration of action.</description>
        <time_frame>Hospital admission to date the positive heparin PF-4 antibody test was drawn, or 28 days prior to the date it was drawn, whichever is later, through the date it was drawn</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIT-T</title>
            <description>Positive heparin-PF4 ELISA test and a thrombotic event associated with heparin exposure within the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), with or without thrombocytopenia.</description>
          </group>
          <group group_id="O2">
            <title>Isolated HIT</title>
            <description>Positive heparin-PF4 ELISA test and a nadir platelet count &lt;50% of baseline platelet count associated with heparin exposure in the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), without a thrombotic event.</description>
          </group>
          <group group_id="O3">
            <title>No HIT</title>
            <description>Positive heparin-PF4 ELISA test with heparin exposure in the preceding 5 days, but not meeting criteria for HIT-T or isolated HIT.</description>
          </group>
        </group_list>
        <measure>
          <title>Type of Heparin Exposure - Low Molecular Weight Heparin (LMWH)</title>
          <description>Two types of heparins are commonly used as anticoagulants - unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH). LMWHs are derived from UFH by depolymerization. Each LMWH product has a specific molecular weight distribution that determines its anticoagulant activity and duration of action.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of subjects with heparin exposure:LMWH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects without heparin exposure:LMWH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="236"/>
                    <measurement group_id="O3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <p_value_desc>P-value is to compare three groups.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship of the Heparin PF-4 (Platelet Factor 4) Antibody Titer to the Clinical Diagnosis</title>
        <description>Heparin PF-4 (platelet factor 4) optical density (OD) test results were the dichotomous outcome (&lt;1.0 vs. &gt;=1.0). Clinical diagnosis was three groups (HIT-T, Isolated HIT and No HIT). The Heparin PF-4 optical density test looks for antibodies to complexes of heparin combined with platelet factor 4. Higher optical density indicates higher antibody concentration. We could say that generally OD values above 0.4 are considered a positive result, and that the higher the OD, the greater the concentration of antibodies in the patient's blood.</description>
        <time_frame>From the time the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
        <population>There was one missing data for optical density test results in Isolated HIT group. Therefore, 283 subjects were used for Isolated HIT group.</population>
        <group_list>
          <group group_id="O1">
            <title>HIT-T</title>
            <description>Positive heparin-PF4 ELISA test and a thrombotic event associated with heparin exposure within the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), with or without thrombocytopenia.</description>
          </group>
          <group group_id="O2">
            <title>Isolated HIT</title>
            <description>Positive heparin-PF4 ELISA test and a nadir platelet count &lt;50% of baseline platelet count associated with heparin exposure in the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), without a thrombotic event.</description>
          </group>
          <group group_id="O3">
            <title>No HIT</title>
            <description>Positive heparin-PF4 ELISA test with heparin exposure in the preceding 5 days, but not meeting criteria for HIT-T or isolated HIT.</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship of the Heparin PF-4 (Platelet Factor 4) Antibody Titer to the Clinical Diagnosis</title>
          <description>Heparin PF-4 (platelet factor 4) optical density (OD) test results were the dichotomous outcome (&lt;1.0 vs. &gt;=1.0). Clinical diagnosis was three groups (HIT-T, Isolated HIT and No HIT). The Heparin PF-4 optical density test looks for antibodies to complexes of heparin combined with platelet factor 4. Higher optical density indicates higher antibody concentration. We could say that generally OD values above 0.4 are considered a positive result, and that the higher the OD, the greater the concentration of antibodies in the patient's blood.</description>
          <population>There was one missing data for optical density test results in Isolated HIT group. Therefore, 283 subjects were used for Isolated HIT group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="283"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Optical density Results less than 1.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="163"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Optical density Results greater or equal to 1.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>P-value is to compare three groups.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship of the Heparin PF-4 Antibody Titer to the Degree of Thrombocytopenia</title>
        <description>Heparin PF-4 optical density (OD) test results were the dichotomous outcome (&lt;1.0 vs. &gt;=1.0). Nadir Platelet Count (x10^9 / L) was used for the degree of thrombocytopenia. The Heparin PF-4 optical density test looks for antibodies to complexes of heparin combined with platelet factor 4. Higher optical density indicates higher antibody concentration. We could say that generally OD values above 0.4 are considered a positive result, and that the higher the OD, the greater the concentration of antibodies in the patient's blood.</description>
        <time_frame>From the time the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OD Result &lt; 1.0</title>
            <description>Heparin-PF4 OD Test Results &lt; 1.0</description>
          </group>
          <group group_id="O2">
            <title>OD Result &gt;= 1.0</title>
            <description>Heparin-PF4 OD Test Results &gt;= 1.0</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship of the Heparin PF-4 Antibody Titer to the Degree of Thrombocytopenia</title>
          <description>Heparin PF-4 optical density (OD) test results were the dichotomous outcome (&lt;1.0 vs. &gt;=1.0). Nadir Platelet Count (x10^9 / L) was used for the degree of thrombocytopenia. The Heparin PF-4 optical density test looks for antibodies to complexes of heparin combined with platelet factor 4. Higher optical density indicates higher antibody concentration. We could say that generally OD values above 0.4 are considered a positive result, and that the higher the OD, the greater the concentration of antibodies in the patient's blood.</description>
          <units>X10^9 / L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.7" spread="92.4"/>
                    <measurement group_id="O2" value="83.1" spread="76.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship of the Heparin PF-4 Antibody Titer to the Primary Endpoint</title>
        <description>Heparin PF-4 OD test results were the dichotomous outcome (&lt;1.0 vs. &gt;=1.0). Primary endpoint was the composite endpoint of death, limb amputation/gangrene, or new thrombosis.</description>
        <time_frame>From the time the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OD Result &lt; 1.0</title>
            <description>Heparin-PF4 OD Test Results &lt; 1.0</description>
          </group>
          <group group_id="O2">
            <title>OD Result &gt;= 1.0</title>
            <description>Heparin-PF4 OD Test Results &gt;= 1.0</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship of the Heparin PF-4 Antibody Titer to the Primary Endpoint</title>
          <description>Heparin PF-4 OD test results were the dichotomous outcome (&lt;1.0 vs. &gt;=1.0). Primary endpoint was the composite endpoint of death, limb amputation/gangrene, or new thrombosis.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No composite endpoint</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Regression, Cox</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Treatment (Non-heparin Anticoagulant) Used in Hospital</title>
        <description>Types of treatment (direct thrombin inhibitor, fondaparinux, warfarin, no treatment) provided to subjects in hospital</description>
        <time_frame>From the time that the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIT-T</title>
            <description>Positive heparin-PF4 ELISA test and a thrombotic event associated with heparin exposure within the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), with or without thrombocytopenia.</description>
          </group>
          <group group_id="O2">
            <title>Isolated HIT</title>
            <description>Positive heparin-PF4 ELISA test and a nadir platelet count &lt;50% of baseline platelet count associated with heparin exposure in the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), without a thrombotic event.</description>
          </group>
          <group group_id="O3">
            <title>No HIT</title>
            <description>Positive heparin-PF4 ELISA test with heparin exposure in the preceding 5 days, but not meeting criteria for HIT-T or isolated HIT.</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Treatment (Non-heparin Anticoagulant) Used in Hospital</title>
          <description>Types of treatment (direct thrombin inhibitor, fondaparinux, warfarin, no treatment) provided to subjects in hospital</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of subjects with treatment in hospital</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="167"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects without treatment in hospital</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="117"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>P-value is to compare three groups.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Occurrence of a Composite Triple Endpoint Consisting of Death, Limb Amputation/Gangrene, and New Thrombosis</title>
        <description>The mean time to an event is estimated by the area under the survival function. If the largest time is an event time, then the survival function goes to zero at that time, and the mean survival estimate is finite. Otherwise, the mean time cannot be estimated and may lead to a bias.</description>
        <time_frame>From the time that the positive heparin PF-4 antibody test was drawn until hospital discharge or day 45, whichever occurred first.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIT-T</title>
            <description>Positive heparin-PF4 ELISA test and a thrombotic event associated with heparin exposure within the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), with or without thrombocytopenia.</description>
          </group>
          <group group_id="O2">
            <title>Isolated HIT</title>
            <description>Positive heparin-PF4 ELISA test and a nadir platelet count &lt;50% of baseline platelet count associated with heparin exposure in the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), without a thrombotic event.</description>
          </group>
          <group group_id="O3">
            <title>No HIT</title>
            <description>Positive heparin-PF4 ELISA test with heparin exposure in the preceding 5 days, but not meeting criteria for HIT-T or isolated HIT.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Occurrence of a Composite Triple Endpoint Consisting of Death, Limb Amputation/Gangrene, and New Thrombosis</title>
          <description>The mean time to an event is estimated by the area under the survival function. If the largest time is an event time, then the survival function goes to zero at that time, and the mean survival estimate is finite. Otherwise, the mean time cannot be estimated and may lead to a bias.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="1.66"/>
                    <measurement group_id="O2" value="27.8" spread="1.30"/>
                    <measurement group_id="O3" value="31.4" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.35</ci_lower_limit>
            <ci_upper_limit>4.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>2.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Occurrence of a Composite Triple Endpoint Consisting of Death, Limb Amputation/Gangrene, and New Thrombosis</title>
        <description>The median survival time is reported by each group for the time to occurrence of a composite triple endpoint consisting of death, limb amputation/gangrene, and new thrombosis.</description>
        <time_frame>From the time that the positive heparin PF-4 antibody test was drawn until hospital discharge or day 45, whichever occurred first.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIT-T</title>
            <description>Positive heparin-PF4 ELISA test and a thrombotic event associated with heparin exposure within the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), with or without thrombocytopenia.</description>
          </group>
          <group group_id="O2">
            <title>Isolated HIT</title>
            <description>Positive heparin-PF4 ELISA test and a nadir platelet count &lt;50% of baseline platelet count associated with heparin exposure in the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), without a thrombotic event.</description>
          </group>
          <group group_id="O3">
            <title>No HIT</title>
            <description>Positive heparin-PF4 ELISA test with heparin exposure in the preceding 5 days, but not meeting criteria for HIT-T or isolated HIT.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Occurrence of a Composite Triple Endpoint Consisting of Death, Limb Amputation/Gangrene, and New Thrombosis</title>
          <description>The median survival time is reported by each group for the time to occurrence of a composite triple endpoint consisting of death, limb amputation/gangrene, and new thrombosis.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="9.0">Due to lack of events, the upper interval of the median survival time could not be estimated.</measurement>
                    <measurement group_id="O2" value="33.0" lower_limit="25.0">Due to lack of events, the upper interval of the median survival time could not be estimated.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="29.0">Due to lack of events, the median survival time and the upper interval could not be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Treatment (Non-heparin Anticoagulant) Used at the Time of Discharge</title>
        <time_frame>From the time that the positive heparin PF-4 antibody test was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIT-T</title>
            <description>Positive heparin-PF4 ELISA test and a thrombotic event associated with heparin exposure within the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), with or without thrombocytopenia.</description>
          </group>
          <group group_id="O2">
            <title>Isolated HIT</title>
            <description>Positive heparin-PF4 ELISA test and a nadir platelet count &lt;50% of baseline platelet count associated with heparin exposure in the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), without a thrombotic event.</description>
          </group>
          <group group_id="O3">
            <title>No HIT</title>
            <description>Positive heparin-PF4 ELISA test with heparin exposure in the preceding 5 days, but not meeting criteria for HIT-T or isolated HIT.</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Treatment (Non-heparin Anticoagulant) Used at the Time of Discharge</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="284"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of subjects with treatment at discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="159"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of subjects with no treatment at discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="125"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>P-value is to compare three groups.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Platelet Recovery, Among Subjects With a Low Platelet Count When the Positive PF4 Antibody Test Was Drawn</title>
        <time_frame>From the time that the nadir platelet count was drawn until hospital discharge, death, or day 45, whichever occurred first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIT-T</title>
            <description>Positive heparin-PF4 ELISA test and a thrombotic event associated with heparin exposure within the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), with or without thrombocytopenia.</description>
          </group>
          <group group_id="O2">
            <title>Isolated HIT</title>
            <description>Positive heparin-PF4 ELISA test and a nadir platelet count &lt;50% of baseline platelet count associated with heparin exposure in the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), without a thrombotic event.</description>
          </group>
          <group group_id="O3">
            <title>No HIT</title>
            <description>Positive heparin-PF4 ELISA test with heparin exposure in the preceding 5 days, but not meeting criteria for HIT-T or isolated HIT.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Platelet Recovery, Among Subjects With a Low Platelet Count When the Positive PF4 Antibody Test Was Drawn</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="249"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.16" spread="0.92"/>
                    <measurement group_id="O2" value="5.16" spread="0.38"/>
                    <measurement group_id="O3" value="2.96" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>HIT-RADIO was a retrospective study so there were no adverse events collected/reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>HIT-T</title>
          <description>Positive heparin-PF4 ELISA test and a thrombotic event associated with heparin exposure within the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), with or without thrombocytopenia.</description>
        </group>
        <group group_id="E2">
          <title>Isolated HIT</title>
          <description>Positive heparin-PF4 ELISA test and a nadir platelet count &lt;50% of baseline platelet count associated with heparin exposure in the preceding 5 days (and with the onset of a platelet count drop of &gt;15% beginning within 5-10 days after starting heparin), without a thrombotic event.</description>
        </group>
        <group group_id="E3">
          <title>No HIT</title>
          <description>Positive heparin-PF4 ELISA test with heparin exposure in the preceding 5 days, but not meeting criteria for HIT-T or isolated HIT.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All publications and presentations resulting from studies from the TMH Network must be approved by the Publications and Presentations Committee before submission. The Sponsor (NERI) and funding agency (NHLBI) both are represented on the P&amp;P Committee along with Network Investigators. Members of the P&amp;P Committee can recommend changes to publications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Susan Assmann, Principal Research Scientist</name_or_title>
      <organization>New England Research Institutes</organization>
      <phone>617-972-3048</phone>
      <email>sassmann@neriscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

